Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

doi:10.1016/j.ygyno.2016.02.025

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Gynecologic oncology - 1 Apr 2016

Myers Andrea P, Filiaci Virginia L, Zhang Yuping, Pearl Michael, Behbakht Kian, Makker Vicky, Hanjani Parviz, Zweizig Susan, Burke James J, Downey Gordon, Leslie Kimberly K, Van Hummelen Paul, Birrer Michael J, Fleming Gini F

Abstract excerpt

OBJECTIVE: Rapamycin analogs have reproducible but modest efficacy in endometrial cancer (EC). Identification of molecular biomarkers that predict benefit could guide clinical development. METHODS: Fixed primary tissue and whole blood were collected prospectively from patients enrolled on GOG 248. DNA was isolated from macro-dissected tumors and blood; next-generation sequence analysis was performed on a panel of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endometrial Neoplasms

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to PTEN Phosphohydrolase

Share to Sirolimus

Share to Tamoxifen

Share to Tuberous Sclerosis Complex 1 Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 27016228
DOI: 10.1016/j.ygyno.2016.02.025
PMCID: PMC5119517

Genes

AKT1
CTNNB1
PTEN
TSC1
TSC2
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.PMID 27016228Read ↗

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.Semantic proximity Read ↗

Molecular Guided Treatments in Gynecologic Oncology: Analysis of a Real-World Precision Cancer Medicine Platform.Semantic proximity Read ↗

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.Semantic proximity Read ↗

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.Semantic proximity Read ↗

Genetic alterations in endometrial cancer by targeted next-generation sequencing.Semantic proximity Read ↗

Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.Semantic proximity Read ↗

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.Semantic proximity Read ↗

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.Semantic proximity Read ↗

Efficacy of Antitumor Drugs Against Uterine Leiomyosarcoma Obtained Through the Analysis of LMP2-Deficient Mice and the Result from a Cancer Gene Panel at Cancer Genomic MedicineSemantic proximity Read ↗

Updates in therapy for uterine serous carcinomaSemantic proximity Read ↗

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146Semantic proximity Read ↗

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.